OBJECTIVE: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. DATA SOURCES: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. DATA SYNTHESIS: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, beta-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. CONCLUSIONS: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.
OBJECTIVE: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. DATA SOURCES: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. DATA SYNTHESIS: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, beta-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. CONCLUSIONS: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.
Authors: Lujian Liao; Dongmei Cheng; Jian Wang; Duc M Duong; Tatyana G Losik; Marla Gearing; Howard D Rees; James J Lah; Allan I Levey; Junmin Peng Journal: J Biol Chem Date: 2004-06-25 Impact factor: 5.157
Authors: L Adrienne Cupples; Lindsay A Farrer; A Dessa Sadovnick; Norman Relkin; Peter Whitehouse; Robert C Green Journal: Genet Med Date: 2004 Jul-Aug Impact factor: 8.822
Authors: V La Bella; M Liguori; R Cittadella; N Settipani; T Piccoli; I Manna; A Quattrone; F Piccoli Journal: Eur J Neurol Date: 2004-08 Impact factor: 6.089
Authors: Y Wakutani; K Watanabe; Y Adachi; K Wada-Isoe; K Urakami; H Ninomiya; T C Saido; T Hashimoto; T Iwatsubo; K Nakashima Journal: J Neurol Neurosurg Psychiatry Date: 2004-07 Impact factor: 10.154
Authors: Feng Chen; M Axel Wollmer; Frederic Hoerndli; Gerald Münch; Björn Kuhla; Evgeny I Rogaev; Magdalini Tsolaki; Andreas Papassotiropoulos; Jürgen Götz Journal: Proc Natl Acad Sci U S A Date: 2004-05-05 Impact factor: 11.205
Authors: Bart Dermaut; Samir Kumar-Singh; Sebastian Engelborghs; Jessie Theuns; Rosa Rademakers; Jos Saerens; Barbara A Pickut; Karin Peeters; Marleen van den Broeck; Krist'l Vennekens; Stephen Claes; Marc Cruts; Patrick Cras; Jean-Jacques Martin; Christine Van Broeckhoven; Peter Paul De Deyn Journal: Ann Neurol Date: 2004-05 Impact factor: 10.422
Authors: G Rossi; G Giaccone; R Maletta; M Morbin; R Capobianco; M Mangieri; A R Giovagnoli; A Bizzi; C Tomaino; M Perri; M Di Natale; F Tagliavini; O Bugiani; A C Bruni Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: Victor P Andreev; Vladislav A Petyuk; Heather M Brewer; Yuliya V Karpievitch; Fang Xie; Jennifer Clarke; David Camp; Richard D Smith; Andrew P Lieberman; Roger L Albin; Zafar Nawaz; Jimmy El Hokayem; Amanda J Myers Journal: J Proteome Res Date: 2012-05-17 Impact factor: 4.466
Authors: Eric M Reiman; Kewei Chen; Richard J Caselli; Gene E Alexander; Daniel Bandy; Jennifer L Adamson; Wendy Lee; Ashley Cannon; Elizabeth A Stephan; Dietrich A Stephan; Andreas Papassotiropoulos Journal: Neuroimage Date: 2008-01-17 Impact factor: 6.556